Payment overview · 2025
General Payments
$136.41
8 reported records · 8 companies
Healthcare provider profile · identity verified
Robbie Boyd Marcantel, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · JENA, LA · NPI 1659345502
Verified facts
What the public records show
CMS Open Payments records show Robbie Boyd Marcantel, PAC received $136.41 in general payments during 2025 across 8 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.70 | 13.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.30 | 13.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.78 | 13.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.17 | 12.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.74 | 12.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.44 | 12.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.29 | 11.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.99 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.41 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 269 | 69 |
| Atorvastatin Calcium | Atorvastatin Calcium | 245 | 53 |
| Gabapentin | Gabapentin | 211 | 39 |
| Omeprazole | Omeprazole | 203 | 43 |
| Lisinopril | Lisinopril | 197 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 33 |
| Losartan Potassium | Losartan Potassium | 131 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 15 |
| Potassium Chloride | Potassium Chloride | 122 | 32 |
| Metformin Hcl | Metformin Hcl | 110 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 92 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 90 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 17 |
| Furosemide | Furosemide | 81 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 33 |
| Montelukast Sodium | Montelukast Sodium | 71 | 20 |
| Ozempic | Semaglutide | 71 | 13 |
| Trazodone Hcl | Trazodone Hcl | 69 | 15 |
| Alendronate Sodium | Alendronate Sodium | 68 | 13 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Meloxicam | Meloxicam | 68 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 17 |
| Farxiga | Dapagliflozin Propanediol | 60 | 11 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Allopurinol | Allopurinol | 50 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Azithromycin | Azithromycin | 46 | 39 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Eliquis | Apixaban | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 13 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 13 |
| Diazepam | Diazepam | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 19 |
| Carvedilol | Carvedilol | 27 | suppressed |
| Niacin Er | Niacin | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | 11 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.41 · 8 records | Takeda Pharmaceuticals U.S.A., Inc. | AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Ohtuvayre, QULIPTA, REPATHA, TRINTELLIX, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trintellix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error